Erosion of the principal investigator role in a climate of industry dominanceROWINSKY, Eric K.European journal of cancer (1990). 2005, Vol 41, Num 15, pp 2206-2209, issn 0959-8049, 4 p.Article

Targeted induction of apoptosis in cancer management : The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agentsROWINSKY, Eric K.Journal of clinical oncology. 2005, Vol 23, Num 36, pp 9394-9407, issn 0732-183X, 14 p.Article

Novel Applications of Imatinib in OncologyROWINSKY, Eric K.Seminars in oncology. 2004, Vol 31, Num 2, issn 0093-7754, 37 p., SUP6Serial Issue

Inhibiting signal transduction: Recent advances in the development of receptor tyrosine kinase and Ras inhibitorsHAO, Desirée; ROWINSKY, Eric K.Cancer investigation. 2002, Vol 20, Num 3, pp 387-404, issn 0735-7907Article

Increasing tumor uptake of anticancer drugs with imatinibPIETRAS, Kristian.Seminars in oncology. 2004, Vol 31, Num 2, pp 18-23, issn 0093-7754, 6 p., SUP6Article

Molecularly targeted treatment for dermatofibrosarcoma protuberansMCARTHUR, Grant.Seminars in oncology. 2004, Vol 31, Num 2, pp 30-36, issn 0093-7754, 7 p., SUP6Article

Raf : A strategic target for therapeutic development against cancerBEERAM, Muralidhar; PATNALK, Amita; ROWINSKY, Eric K et al.Journal of clinical oncology. 2005, Vol 23, Num 27, pp 6771-6790, issn 0732-183X, 20 p.Article

Role of KIT and platelet-derived growth factor receptors as oncoproteinsFLETCHER, Jonathan A.Seminars in oncology. 2004, Vol 31, Num 2, pp 4-11, issn 0093-7754, 8 p., SUP6Article

The rapamycin-sensitive signal transduction pathway as a target for cancer therapyHIDALGO, Manuel; ROWINSKY, Eric K.Oncogene (Basingstoke). 2000, Vol 19, Num 56, pp 6680-6686, issn 0950-9232Article

Dose-intense paclitaxel: Déjà vu all over again?TAKIMOTO, Chris H; ROWINSKY, Eric K.Journal of clinical oncology. 2003, Vol 21, Num 15, pp 2810-2814, issn 0732-183X, 5 p.Article

Phase II study of 4-Ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinomaLAKHANPAL, Shailendra; DONEHOWER, Ross C; ROWINSKY, Eric K et al.Investigational new drugs. 2001, Vol 19, Num 1, pp 69-76, issn 0167-6997Article

The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agentsROWINSKY, Eric K.Drugs (Basel). 2000, Vol 60, pp 1-14, issn 0012-6667, SUP1Article

Novel agents that target tublin and related elementsROWINSKY, Eric K; CALVO, Emiliano.Seminars in oncology. 2006, Vol 33, Num 4, pp 421-435, issn 0093-7754, 15 p.Article

Farnesyltransferase inhibitors and their potential in the treatment of breast carcinomaDE BONO, Johann S; TOLCHER, Anthony W; ROWINSKY, Eric K et al.Seminars in oncology. 2003, Vol 30, Num 5, pp 79-92, issn 0093-7754, 14 p., SUP16Conference Paper

The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellumO'REILLY, Seamus; O'HEARN, Elizabeth; STRUCK, Robert F et al.Investigational new drugs. 2003, Vol 21, Num 3, pp 269-279, issn 0167-6997, 11 p.Article

Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancerMATHEW, Paul; FIDLER, Isaiah J; LOGOTHETIS, Christopher J et al.Seminars in oncology. 2004, Vol 31, Num 2, pp 24-29, issn 0093-7754, 6 p., SUP6Article

Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignanciesROWINSKY, Eric K.Clinical cancer research. 2004, Vol 10, Num 12, pp 4220s-4226s, issn 1078-0432, 2Conference Paper

Targeting FMS-Related Tyrosine Kinase Receptor 3 With the Human Immunoglobulin G1 Monoclonal Antibody IMC-EB10YOUSSOUFIAN, Hagop; ROWINSKY, Eric K; TONRA, James et al.Cancer. 2010, Vol 116, Num 4, pp 1013-1017, issn 0008-543X, 5 p., SUPConference Paper

Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndromeSTONE, Richard M; GILLILAND, D. Gary; KLION, Amy D et al.Seminars in oncology. 2004, Vol 31, Num 2, pp 12-17, issn 0093-7754, 6 p., SUP6Article

Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced MalignanciesMITA, Monica; KELLY, Kevin R; GILES, Francis J et al.Clinical cancer research (Print). 2011, Vol 17, Num 1, pp 193-200, issn 1078-0432, 8 p.Article

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC PatientsWINDER, Thomas; WU ZHANG; ROWINSKY, Eric K et al.Clinical cancer research (Print). 2010, Vol 16, Num 22, pp 5591-5602, issn 1078-0432, 12 p.Article

Vascular Endothelial Growth Factor Receptor-1 in Human Cancer: Concise Review and Rationale for Development of IMC-18F1 (Human Antibody Targeting Vascular Endothelial Growth Factor Receptor-1)SCHWARTZ, Jonathan D; ROWINSKY, Eric K; YOUSSOUFIAN, Hagop et al.Cancer. 2010, Vol 116, Num 4, pp 1027-1032, issn 0008-543X, 6 p., SUPConference Paper

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid TumorsMITA, Alain C; DENIS, Louis J; SEMIOND, Dorothée et al.Clinical cancer research (Print). 2009, Vol 15, Num 2, pp 723-730, issn 1078-0432, 8 p.Article

A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignanciesROWINSKY, Eric K; BEERAM, Muralidhar; NGUYEN, Binh et al.Clinical cancer research. 2007, Vol 13, Num 2, pp 532-539, issn 1078-0432, 8 p., 1Article

Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogueLEE, Carlton K. K; ROWINSKY, Eric K; JING LI et al.Clinical cancer research. 2006, Vol 12, Num 7, pp 2158-2165, issn 1078-0432, 8 p., 1Article